[1]罗 银,吴雨欣,杨赐然,等.湖北省国谈药可获得性研究 ——基于公立医院和零售药店的数据分析[J].卫生经济研究,2024,41(08):8-12.
　LUO Yin,WU Yuxin,YANG Ciran,et al.Study on the Availability of National Negotiated Drugs in Hubei Province ——Based on the Data Analysis of Public Hospitals and Retail Pharmacies[J].Journal Press of Health Economics Research,2024,41(08):8-12.
点击复制

湖北省国谈药可获得性研究
——基于公立医院和零售药店的数据分析
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
41
期数:
2024年08期
页码:
8-12
栏目:
专题研究
出版日期:
2024-08-01

文章信息/Info

Title:
Study on the Availability of National Negotiated Drugs in Hubei Province
——Based on the Data Analysis of Public Hospitals and Retail Pharmacies
作者:
罗 银1; 2; 吴雨欣1; 2; 杨赐然1; 2; 崔 丹1; 2
1.武汉大学公共卫生学院，湖北 武汉 430071
2.武汉大学全球健康研究中心，湖北 武汉 430072
Author(s):
LUO Yin;  WU Yuxin;  YANG Ciran;  CUI Dan
School of Public Health, Wuhan University,Wuhan Hubei 430071, China
关键词:
国家谈判药品; 可获得性; 公立医院; 零售药店
Keywords:
national negotiated drugs;  availability;  public hospitals;  retail pharmacies
分类号:
R19
文献标志码:
A
摘要:
目的：评估国谈药在湖北省公立医院和零售药店的可获得性，为完善国谈药“落地”配套政策提供参考。方法：借鉴 WHO/HAI 标准药品调查法，通过品种配备率和可获得率指标，分析2022年处于协议期内275个国谈药在湖北省公立医院和零售药店的可获得性。结果：2022年湖北省国谈药在公立医院的可获得率为77.62%，各市州、各级别医药机构之间存在差距，国谈药各品种和各批次之间也存在明显差距；药店渠道的扩充使国谈药品种配备率提升。结论：国谈药在湖北省的“落地”供应存在地区差异，引入药店渠道能有效改善国谈药配备使用的公平性；需在政策设计上强化激励机制，引导公立医院配备使用国谈药，同时不断完善“双通道”药店管理机制，确保用药安全。
Abstract:
Objective To evaluate the availability of national negotiated drugs in public hospitals and retail pharmacies in Hubei Province, and to provide reference for improving the supporting policies for the implementation of national negotiated drugs. Methods Drawing on the WHO/HAI standard drug survey method, the availability of 275 national negotiated drugs within the agreement period in public hospitals and retail pharmacies in Hubei Province in 2022 were analyzed by using the indicators of varieties allocation rate and availability rate. Results The availability rate of national negotiated drugs in public hospitals in Hubei Province in 2022 was 77.62%. However, there were significant differences in the availability of national negotiated drugs among cities and states, institutions at different levels, varieties and batches of drugs. The expansion of the pharmacy channels increased the allocation rate of national negotiated drugs. Conclusion There are regional differences in the supply of national negotiated drugs in Hubei Province, and the introduction of pharmacy channels can effectively improve the fairness of the provision and use of national negotiated drugs. It is necessary to strengthen the incentive mechanism in policy design to guide public hospitals to provide and use national negotiated drugs, and at the same time, continuously improve the "dual channel" pharmacy management mechanism to ensure the safety of drugs.

参考文献/References:

[1] 胡善联.中国医保药品价格谈判回顾和展望[J].卫生经济研究，2024，41（01）：9-13.
[2] 顾一纯，何达，孙辉，等.基于史密斯政策执行过程模型的国家医保药品目录准入谈判罕见病药品落地问题及路径研究[J].中国卫生资源，2023，26（04）：363-369.
[3] 陈玲玲，徐伟，尚波波，等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究，2020，37（12）：17-20.
[4] 李伟，陈红斗，陆伟，等.2016—2021年国家医保谈判药品可及性研究——基于全国大数据的实证分析[J].中国现代应用药学，2023， 40（10）：1405-1410.
[5] 彭瑾，蒋俊男，邱增辉，等.国家医保谈判药品在浙江省三级医疗机构的落地实践[J].中国药房，2023，34（10）：1159-1164.
[6] 陈红斗，李伟，陆伟，等.2020-2021年我国国家医保谈判抗肿瘤药物的可及性及应用分析[J].中国医院药学杂志，2023，43（05）：530-535.
[7] 管晓东，信枭雄，刘洋，等.我国基本药物可获得性评价实证研究[J].中国药房，2013，24（24）：2216-2219.
[8] Mendis S，Fukino K，Cameron A，et al.The availability and affordability of selected essential medicines for chronic diseases in six low- and middle-income countries[J].Bulletin of the World Health Organisation，2007，85(04):279-288.
[9] 谢金平，邵蓉.国家医保谈判药品省级落地管理典型模式研究[J].中国卫生经济，2020，39（06）：42-46.
[10] 邱志国，柯磊，万元胜，等.国家医保谈判药品在某院可及性的现状和影响因素研究[J].中国医院药学杂志，2022，42（18）：1918-1922.
[11] 陈金燃，郭凯宁，陈纯，等.2018-2019年福建省国家谈判药品患者用药可及性调研分析[J].中国医疗保险，2020（12）：59-64.
[12] 张钰婉，谈在祥，卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究，2022，39（04）：15-18，23.

相似文献/References:

[1]路 云,张闪闪,李世勇.江苏省基本药物制度实施效果评价与思考[J].卫生经济研究,2017,(10):45.
[2]刘 昉,李翠翠,马 健,等.基层用药公平可及性评价研究[J].卫生经济研究,2018,(04):46.
[3]吴玉霞,徐 伟,蔡功杰,等.基本药物可获得性影响因素研究——基于25省监测点数据的实证分析[J].卫生经济研究,2018,(12):37.
　WU Yu-xia,XU Wei,CAI Gong-jie,et al.Study on the Factors Affecting the Availability of Essential Drugs——An Empirical Analysis Based on Data from 25 Provinces[J].Journal Press of Health Economics Research,2018,(08):37.
[4]李孟林,徐 伟,杜雯雯,等.我国上市专利药品可获得性实证研究[J].卫生经济研究,2019,(12):59.
　LI Meng-lin,XU Wei,DU Wen-wen,et al.Empirical Study on the Availability of Patented Drugs in China[J].Journal Press of Health Economics Research,2019,(08):59.
[5]梁 冰,王前强,陈凤磊,等.国家谈判药品对综合医院医保管理的影响及对策[J].卫生经济研究,2020,(05):42.
　LIANG Bing,WANG Qian-qiang,CHEN Feng-lei,et al.Impact of National Negotiation Drugs on Medical Insurance Management in General Hospitals and Countermeasures[J].Journal Press of Health Economics Research,2020,(08):42.
[6]严 晶,张 燕.DRG付费下国家谈判药品政策落地的实践[J].卫生经济研究,2021,38(12):20.
　YAN Jing,ZHANG Yan.Practice of National Negotiated Drug Policy Implementation under DRG Payment[J].Journal Press of Health Economics Research,2021,38(08):20.
[7]张钰婉,谈在祥,卢亚娟.国家谈判药品“双通道”模式实施现状及优化建议——以S市为例[J].卫生经济研究,2022,39(4):15.
　ZHANG Yu-wan,TAN Zai-xiang,LU Ya-juan.Implementation Status and Optimized Suggestions of the "Dual-Channel" Model for National Negotiation Drugs——Taking S City as An Example[J].Journal Press of Health Economics Research,2022,39(08):15.
[8]曹 庄,李赛赛,曹人元,等.国家医保谈判药品落地情况研究——基于5市17种国谈抗癌药使用及报销数据的分析[J].卫生经济研究,2022,39(7):53.
　CAO Zhuang,LI Saisai,CAO Renyuan,et al.Research on the Accessibility of National Medical Insurance Negotiation Drugs ——An Analysis Based on the Usage and Reimbursement Data of 17 National Negotiated Anticancer Drugs in Five Cities[J].Journal Press of Health Economics Research,2022,39(08):53.
[9]王宁锋,李雪竹,张 慧.国谈药单行支付政策研究[J].卫生经济研究,2024,41(06):16.
　WANG Ningfeng,LI Xuezhu,ZHANG Hui.Study on One-way Payment Policy for the State-negotiated Drugs[J].Journal Press of Health Economics Research,2024,41(08):16.
[10]郭孟子,李紫航,陈艺璇,等.“三医”协同视角下国谈药“双通道”高质量发展研究[J].卫生经济研究,2024,41(08):4.
　GUO Mengzi,LI Zihang,CHEN Yixuan,et al.Study on the High-quality Development of the "Dual channel" of National Negotiated Drugs from the Perspective of "Three Medical" Synergy[J].Journal Press of Health Economics Research,2024,41(08):4.
[11]陈玲玲,徐 伟,尚波波,等.国家谈判药品可获得性研究——基于苏州市公立医院采购数据的实证分析[J].卫生经济研究,2020,(12):17.
　CHEN Ling-ling,XU Wei,SHANG Bo-bo,et al.Research on the Availability of National Negotiated Drugs——An Empirical Analysis Based on the Purchasing Data of Public Hospitals in Suzhou[J].Journal Press of Health Economics Research,2020,(08):17.

更新日期/Last Update: 2024-08-01